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Introduction
The formation of anti-nuclear autoantibodies is the
main feature of the autoimmune disease systemic lupus
erythematosus (SLE). We do not know why these
nuclear components become autoantigens in the
disease. Recently, evidence has emerged which points
to an important connection with apoptosis and the
removal of apoptotic cells. The process of apoptosis, or
programmed cell death, contains a series of pathways
leading to the regulated removal of unwanted cells,
including the induction of tolerance for autoantigens.
This process is strictly regulated. In particular, the
adequate removal of early apoptotic cells is of great
importance. Since nuclear autoantigens become clus-
tered in apoptotic blebs [1], an impaired removal
could lead to the release of nuclear structures, possibly
also modiﬁed during apoptosis (Figure 1). The release
of (modiﬁed) nuclear structures could then induce
an immune response to these autoantigens leading
to the production of autoantibodies. Chromatin, a
complex of proteins and double-stranded (ds) DNA,
is an autoantigen that is clustered in apoptotic blebs.
Autoantibodies against chromatin (including anti-
dsDNA, anti-histone and nucleosome-speciﬁc anti-
bodies) are a hallmark of SLE [2]. Moreover, the
formation of anti-chromatin/chromatin complexes can
lead to the binding of these complexes to basement
membranes, including the glomerular basement mem-
brane (GBM). Here, the positively charged histone tails
of chromatin bind to negatively charged molecules in
the GBM, such as heparan sulphate proteoglycans [3].
This binding induces inﬂammation, which leads to
lupus nephritis, the most serious manifestation of SLE.
The evidence for dysregulation of the apoptotic process
and removal of apoptotic cells for the development of
SLE will be discussed in this Editorial Comment.
Apoptosis and SLE
Apoptosis not only plays a critical role in removing
damaged cells, but is also very important in inducing
and maintaining self-tolerance. Tolerance of self
antigens requires the deletion of autoreactive T- and
B-cells by apoptosis and, therefore, defects in inducing
apoptosis could lead to the persistence of autoreactive
T- or B-cells. The ﬁrst evidence for the relation between
apoptosis and SLE came from amouse model involving
a defect in an apoptosis-inducing system, the Fas/Fas
ligand (FasL) system [4]. Mice deﬁcient for either Fas
(lpr) or FasL (gld) develop lymphoproliferation and
autoimmunity. It is important to note that lpr or gld
mutations alone do not cause lupus-like syndromes.
Depending on the genetic background, they can
accelerate the disease expression. Overexpression of
the apoptosis inhibitor Bcl-2 resulted in an increased
number of autoreactive B-cells and autoimmunity,
which again was dependent on the genetic background
[5]. Other apoptotic signal molecules have also been
associated with lupus. Bim, a member of the Bcl-2 pro-
tein family, plays an important role in the induction of
apoptosis in thymocytes and loss of this molecule leads
to the development of fatal autoimmune glomerulone-
phritis [6,7]. Mice heterozygous for Pten, a phosphatase
involved in apoptosis, have an impaired Fas response
and develop disease comparable to Fas-deﬁcient
mutants [8]. Recently, BLys, a member of the tumour
necrosis factor ligand superfamily and known to be
important in B-cell survival, and TACI, an inhibitor of
BLys, have been associated with lupus-like disease.
Overexpression of BLys [9] and loss of TACI [10,11]
resulted in the formation of autoantibodies to nuclear
antigens and immune-complex deposits in the kidney.
In human lupus and in the (NZBNZW)F1 mouse
model, however, the evidence for disturbed apoptosis is
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less clear. Only a quarter of patients with a defect in Fas
or FasL develop anti-nuclear antibodies [12]. In
humans with SLE, the Fas-dependent pathway seems
to be unaffected [12], but some evidence has been found
for upregulation of soluble Fas [13,14] and increased
expression of Bcl-2 [15]. In addition, increased levels of
apoptotic cells have been found in SLE patients [16,17],
but this did not correlate with disease activity and was
also found in non-SLE patients. Moreover, these
elevated levels may also be explained by an elevated
number of circulating lymphocytes prone to apoptosis.
Recently, a polymorphism of a new apoptosis-related
gene, programmed cell death 1 gene (PDCD1), was
linked to SLE [18]. A single-nucleotide polymorphism
altering a binding site for run-related transcription
factor X1 (RUNX1), was found in Nordic SLE patients.
The PDCD1 gene is located in a locus previously linked
to SLE [19]. In summary, especially in certain lupus
mouse models there is a clear association between
abnormal apoptosis and lupus development. In
humans, however, this is less evident.
Removal of apoptotic cells
In addition to a disturbed apoptosis, as described
above, elevated levels of autoantigens might result from
an impaired removal of apoptotic cells. Important for
this hypothesis was the observation of Rosen et al. [1]
that autoantigens, such as DNA, cluster in blebs on the
surface of apoptotic keratinocytes after exposure to UV
light. Normally, apoptotic cells are swiftly removed by
neighbouring cells or, in places where the load of
apoptotic cells is high, by macrophages or other
professional phagocytes. This uptake does not induce a
pro-inﬂammatory response, but rather generates an
anti-inﬂammatory reaction. This rapid non-phlogistic
removal prevents the formation of unstable apoptotic
blebs, which might result in the release of potential
autoantigens. These autoantigens may become
extra immunogenic by modiﬁcations obtained during
apoptosis.
Recognition of apoptotic cells is a complex process,
involving many phagocytic receptors, bridging mole-
cules and markers on the apoptotic cell [20]. The (early)
apoptotic process includes chromatin condensation
and also surface changes on the apoptotic cell, most
notably the appearance of phosphaditylserine (PS) at
the outside. This and other changes provide ‘eat me’
signals to phagocytic cells. These express a number
of receptors able to bind apoptotic cells, including
the PS receptor, CD14, the C1q receptor, the
vitronectin receptor and others. The lipopolysaccharide
(LPS) receptor, CD14, normally induces a pro-inﬂam-
matory response to invading organisms. However,
docking of apoptotic cells results in the opposite effect,
an anti-inﬂammatory reaction. Recently, a new
receptor on the macrophage for apoptotic cells has
been identiﬁed [21]. Macrophages of mice with a
truncated cytoplasmic tail of the MER receptor
Fig. 1. Hypothesis for the development of anti-chromatin responses in SLE. (1) Disturbed apoptosis either at the wrong time-point and/or at
the wrong microenvironment. (2) Defective removal of apoptotic cells leading to the release of apoptotic blebs containing chromatin. (3)
Apoptosis induced chromatin modiﬁcations. (4) Stimulation of the immune response by chromatin. (5) Formation of anti-chromatin/
chromatin complexes. (6) Binding of the complexes to heparan sulphate in basement membranes due to the charge interaction between
cationic N-termini of the core histones and the anionic charged heparan sulphate.










tyrosine kinase (merkd) showed a defect in clearance of
apoptotic cells and development of lupus. This receptor
binds via the protein encoded by the growth arrest-
speciﬁc gene 6 (Gas6) to PS. In addition, certain
‘bridging molecules’ play an important role in the
removal of apoptotic cells. These molecules include
C1q, 2-glycoprotein I, pentraxins such as pentraxin 3
(PTX3), C-reactive protein (CRP), serum amyloid P
protein (SAP) and thrombospondin, and the recently
identiﬁed prothrombin [22] and protein S [23]. Studies
involving these molecules have led to increasing
evidence for a pivotal role of a disturbed removal of
apoptotic cells in SLE [2]. Deﬁciency for C1q or SAP in
mice resulted in an anti-nuclear autoimmune response
and glomerulonephritis. Both molecules, along with
PTX3, not only act as mediators in the removal, but
most likely also play a role in the masking of apoptotic
blebs and autoantigens, such as chromatin, for the
immune system. Recently, this has been underlined by
the binding of SAP to late apoptotic cells. A ‘back-up’
system seems to exist in case the removal of apoptotic
cells is impaired and late apoptotic cells, blebs and/or
autoantigens are released. This system also includes
DNase1, which digests chromatin-derived autoanti-
gens. Mice deﬁcient for DNase1 also develop anti-
nuclear autoimmunity and glomerulonephritis. Indeed,
the involvement of C1q, CRP (functionally related to
SAP) and DNase1 in the genesis of human lupus has
also been found [24–26]. In lupus-prone mice, the
evidence for an impaired removal of apoptotic cells is
not yet clear. We found no constitutive defect in the
uptake of apoptotic cells by macrophages of pre-
morbid lupus-prone mice [27], but recently an impaired
clearance of apoptotic cells by thioglycolate stimulated
macrophages was found in MRL/Mp and (NZW
NZB)F1 mice [27]. This corroborates our ﬁnding that
in diseased lupus mice clearance of apoptotic cells is
impaired.
In summary, increasing evidence is accumulating,
showing that a disturbed removal of apoptotic cells
leads to an anti-nuclear response and the subsequent
development of lupus glomerulonephritis.
Conclusion
The involvement in SLE development of one or more
defects in the induction of apoptosis and, especially, the
removal of apoptotic cells has become clear during the
last decade (Figure 1). Deranged apoptosis, via an
increase or a delay in the wrong microenvironment
and/or a reduced clearance of apoptotic cells, leads
to the release of nuclear autoantigens [2], which in
turn triggers an autoimmune response by autoreactive
nucleosome T-cells after presentation by dendritic
cells or other antigen-presenting cells. This leads to
the production of autoantibodies, such as anti-
chromatin autoantibodies, which through a complex
formation with chromatin become deposited in base-
ment membranes, especially in the skin and the kidney,
where they may cause glomerulonephritis [28].
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Toxic effects, which involve some organs with partic-
ular intensity, are the main disadvantage in the thera-
peutic use of cyclosporin A (CsA). Nephrotoxicity,
renal vascular damage and hypertension are most rele-
vant among the undesirable effects. Vascular injury has
generally been considered a common-ground factor of
all types of CsA-induced organ damage [1–3].
Albeit that vascular smooth muscle cells initially
appeared to be the main CsA target [2], the ﬁnding
of multiple endothelial effects [1,3,4–6] indicates that
endothelial cell (EC) toxicity is an emerging feature of
CsA-induced vascular injury.
Cyclosporin A, endothelium and VEGF
Amain issue related to the mechanisms of the effects of
CsA is the putative involvement of vascular endothelial
growth factor (VEGF) as a relevant cellular response
factor. A reasonable possibility is that VEGF has a key
role in the cytoprotective mechanisms against CsA-
related cell damage and induction of cell resistance
against injury. VEGF exerts its effect after binding
to membrane tyrosine kinase receptors (VEGFR1,
VEGFR2 and VEGFR3, and a complementary
receptor, neuropilin-1). Each of these receptors has
different signal transduction properties and func-
tions, but VEGFR2 is more important in functional
terms [7].
Evidence has shown that circumstances as varied
as hypoxia, exposure to reactive oxygen species
(ROS), ﬁbroblast growth factor-2 or rupture of inter-
endothelial VE cadherin junctions can all stimulate
ECs to produce VEGF [8]. As mentioned above, this
autocrine VEGF expression appears to be related to
a protective mechanism.
In vitro, blockade of autocrine VEGF using a speciﬁc
VEGF blocking antibody (-VEGF) signiﬁcantly
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